Pulmonary arterial hypertension
Authors:
P. Jansa; D. Ambrož; T. Paleček; P. Poláček; J. Marešová; L. Jelínková; M. Aschermann; A. Linhart
Published in the journal:
Kardiol Rev Int Med 2007, 9(3): 145-153
Summary
Pulmonary arterial hypertension (PAH) is a potentially fatal disease of pulmonary arterioles. Genetic predisposition plays a role in the pathophysiology of the disease, as well as a number of exogenous factors which cause endothelial dysfunction and subsequent vasoconstriction, vascular remodelling and thrombosis primarily in the region of small pulmonary arteries. The symptomatology of PAH is non–specific, hence the high rate of late-diagnosed cases of the disease. Patients with higher risk of pulmonary hypertension (i.e. systemic sclerodermia and HIV patients, patients with portal hypertension preceding liver transplantation and first grade relatives of PAH patients) should have preventative echocardiography examinations on a regular basis. The treatment of pulmonary hypertension is extremely complex and expensive, and therefore it is confined to specialised centres. The choice of PAH pharmacotherapy depends on the outcome of the acute pulmonary vasodilator test. Only patients with a positive outcome (11 % of patients) are indicated for the treatment by high doses of calcium channel blockers. This is what we call „conventional“ treatment, together with anticoagulation treatment and the treatment of heart failure. In case of a negative outcome of the test, „specific“ pharmacotherapy (prostanoids, endothelin receptor antagonists, phosphodiesterase 5 inhibitors) with both vasodilator and antiproliferative and antiaggregation effect are indicated in addition to chronic anticoagulation treatment. In patients in NYHA functional class (II) and III, treatment is initiated with bosentan, alternatively with sildenafil. Prostacyclin is the basic therapy in NYHA functional class IV. In a number of cases, monotherapy does not provide optimum response. Combination therapy is a rational alternative in such case, using several specific drugs. Once the possibilities of pharmacotherapy have been exhausted, atrial septostomy and lung transplantation can be considered. In addition to research for better therapeutic procedures for PAH, a major challenge in PAH treatment today is timely and correct diagnosing based on a correctly formulated suspicion. Still toady, great part of PAH patients is referred to specialised centres in advanced stages of the disease.
Keywords:
pulmonary arterial hypertension – conventional treatment – specific treatment – calcium channel blockers – prostanoids – endothelin receptor antagonists – phosphodiesterase 5 inhibitors
Zdroje
1.Riedel M. Klasifikace a nomenklatura plicní hypertenze. Kapitoly z kardiologie 2002; 4: 46–49.
2.Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5–12.
3.Farber HW, Loscalzo J. Pulmonary arterial hypertension – mechanism of disease. N Engl J Med 2004; 351: 1655–1665.
4.Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 1954; 30: 195–207.
5.Nichols WC, Koller DL, Slovis B et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nat Genet 1997; 15: 277–280.
6.Morse JH, Jones AC, Barst RJ et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31–q32. Circulation 1997; 95: 2603–2606.
7.Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor–II gene. Am J Hum Genet 2000; 67: 737–744.
8.Trembath RC, Thomson JR, Machado RD et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325–334.
9.Yuan JJ, Aldinger AM, Juhaszova M et al. Dysfunctional voltage–gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400–1406.
10.Simonneau G, Fartoukh M, Sitbon O et al. Primary pulmonary hypertension associated with the use of fenfluramines derivatives. Chest 1998; 114(Suppl 3): 195–199.
11.HIV–1 Nef is associated with complex pulmonary vascular lesions in SHIV–nef–infected macaques. Am J Respir Crit Care Med 2006; 174: 437–445.
12.Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France. Results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030.
13.Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088–1093.
14.Vongpatanasin W, Brickner ME, Hillis LD et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128: 745–755.
15.D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343–349.
16.Sitbon O, Humbert M, Jais X et al. Long–term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105–3111.
17.Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104: 236–250.
18.McGoon M, Gutterman D, Steen V et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. Chest 2004; 126(Suppl): 14–34.
19.Daniels LB, Krummen DE, Blanchard DG. Echocardiography in pulmonary vascular disease. Cardiol Clin 2004; 22: 383–399.
20.Fuster V, Steele PM, Edwards WD et al. Primary pulmonary hypertension and the importance of thrombosis. Circulation 1984; 70: 580–587.
21.Tuder RM, Cool CD, Geraci MW et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925–1932.
22.Badesch DB, McLaughlin VV, Delcroix M et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004: 43(Suppl): 56–61.
23.Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–301.
24.Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double–blind, randomized, placebo– controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.
25.Barst RJ, Galie N, Naeije R et al. Long–term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195–1203.
26.Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347: 322–329.
27.Opitz CF, Wensel R, Winkler J et al. Clinical efficacy and survival with first–line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005; 26: 1895–1902.
28.Barst RJ, McGoon MD, McLaughlin VV et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119–2125.
29.Nishida M, Eshiro K, Okada Y et al. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline–induced pulmonary hypertension. J Cardiovasc Pharmacol 2004; 44: 187–191.
30.Channick R, Sunomeau G, Sitbon O et al. Effects of the dual endothelin–receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study. Lancet 2001; 358: 1119–1123.
31.Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903.
32.McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first–line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 24: 244–249.
33.Successful study with Tracleerr in patients with mildly symptomatic Pulmonary Arterial Hypertension. Actelion, Media release, 18. Dec. 2006. !!PROSÍM O KONTROLU, ZDA BYLO SPRÁVNĚ DOPLNĚNO!!
34.Barst RJ, Langleben D, Frost A et al for the STRIDE–1 study group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441–447.
35.Barst RJ, Langleben D, Badesch D et al. Treatment of pulmonary arterial hypertension with the selective endothelin–A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049–2056.
36.Galie N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529–535.
37.Cohen AH, Hanson K, Morris K et al. Inhibition of cyclic 3'–5'–guanosin monophosphate–specific phosphodiesterase selectivity vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996; 97: 172–179.
38.Ghofrani HA, Schermuly RT, Rose F et al. Sildenafil for long–term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139–1141.
39.Perimenis P. Sildenafil for the treatment of altitude–induced hypoxaemia. Expert Opin Pharmacother 2005; 6: 835–837.
40.Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157.
41.Benza RL, Park MH, Keogh A et al. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant 2007; 26: 437–446.
42.Doyle RL, McCrory D, Channick RN et al. Surgical treatments/interventions for pulmonary arterial hypertension. Chest 2004; 126(Suppl): 63–71.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2007 Číslo 3
Najčítanejšie v tomto čísle
- Monitoring peroral anticoagulation therapy in outpatient practice
- Importance of implantable loop recorder in patients with unexplaided syncope
- CURRENT MEDICAL LITERATURE LTD, LONDON 1998, 438S.
- Pulmonary arterial hypertension